Skip to main content

Table 2 The association between clinical variables and 5-FU related enzymes in T1G3 patients treated with BCG

From: Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

 

TS (mean ± SE)

DPD (mean ± SE)

OPRT (mean ± SE)

Age

    

 Less than 70 (n = 14)

 

10.58 ± 2.12

1.02 ± 0.23

1.91 ± 0.21

 70 or greater (n = 14)

 

8.23 ± 1.01

1.44 ± 0.26

2.08 ± 0.23

  p value

 

0.664

0.268

0.964

Gender

    

 Men

(n = 23)

9.55 ± 1.34

1.35 ± 0.21

1.88 ± 0.15

 Female

(n = 5)

8.16 ± 1.21

0.87 ± 0.34

2.18 ± 0.44

  p value

 

0.748

0.123

0.748

Concomitant CIS

    

 Yes

(n = 7)

10.80 ± 2.23

0.64 ± 0.21

2.58 ± 0.37

 No

(n = 21)

8.94 ± 1.25

1.31 ± 0.21

1.95 ± 0.15

  p value

 

0.341

0.057

0.054

Multiple disease

    

 Yes

(n = 19)

8.98 ± 1.22

1.57 ± 0.38

1.77 ± 0.17

 No

(n = 9)

10.05 ± 2.26

1.12 ± 0.18

2.26 ± 0.29

  p value

 

0.770

0.534

0.130

LVI

    

 Yes

(n = 18)

9.64 ± 1.33

1.03 ± 0.19

1.91 ± 0.19

 No

(n = 10)

8.72 ± 1.93

1.64 ± 0.32

2.09 ± 0.23

  p value

 

0.547

0.055

0.817

  1. SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion; TS: thymidylate synthase; DPD: dihydropyrimidine dehydrogenase; OPRT: orotate phosphoribosyl transferase.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us